Canadian Nosocomial Infection Surveillance Program (CNISP)

Surveillance Protocol for the Enhanced Hospital Profile (EHP)

Contact Information
Please direct all questions to:

Public Health Agency of Canada
CNISP Surveillance
E-mail: cnisp-pcsin@phac-aspc.gc.ca

Working Group
Jessica Bartoszko* (Epi Lead), Maureen Buchanan-Chell, Kelly Choi*, Charles Frenette (Chair), Jennifer Grant, Jenine Leal, Robyn Mitchell*, Christelle Sessua, Anada Silva*, Stephanie Smith

* Public Health Agency of Canada (PHAC)
# Table of Contents

BACKGROUND ................................................................................................................................. 3  
OBJECTIVES ................................................................................................................................. 3  
METHODS ....................................................................................................................................... 4  
  SITE ELIGIBILITY .......................................................................................................................... 4  
  SUBMISSION TIMELINE .................................................................................................................. 4  
  DATA SUBMISSION ........................................................................................................................ 4  
  ANALYSIS ...................................................................................................................................... 5  
ETHICS ............................................................................................................................................. 5  
PRIVACY ......................................................................................................................................... 5  
APPENDIX 1 – QUESTIONNAIRE ...................................................................................................... 6  
APPENDIX 2 – DATA DICTIONARY ................................................................................................ 15
BACKGROUND

Healthcare-associated infections (HAIs) and antimicrobial resistant organisms (AROs) are a major threat to public health due to their increased morbidity, mortality, healthcare cost and burden on hospitals (1). The World Health Organization and Public Health Agency of Canada both include infection prevention and control, and antimicrobial stewardship as key components in their published action plans to combat antimicrobial resistance (AMR) (2,3). Both are informed by data from surveillance of nosocomial infections and microbiological laboratories, including data on the identification and characterization of AROs.

Infection prevention and control in hospitals aims to reduce the number of HAI/ARO infections with strict adherence to standard practice (e.g. hand hygiene, screening, isolation precautions, targeted infection control measures). These efforts combine with those of antimicrobial stewardship, which aims to preserve the future effectiveness of antimicrobials by reducing their misuse and overuse (2,3). Practices may differ between institutions based on local epidemiology, evolving guidelines, areas of controversial measures and various levels of implementation. Variability in practices may affect outcome measurement as well as ultimate rates of infection. The Enhance Hospital Profile (EHP) provides an opportunity to investigate how differences in these practices affect HAI/ARO rates and clinical outcomes captured by our active surveillance of HAIs/AROs.

Since 2014, the Canadian Nosocomial Infection Surveillance Program (CNISP) has collected data on hospital practices related to the infection prevention and control of HAIs and AROs. These data include the frequency and scope of screening practices for carbapenemase-producing organisms (CPO), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). In 2018, CNISP expanded the EHP to collect data on hospital practices related to screening for Candida auris (C. auris), and laboratory testing and antimicrobial stewardship of AROs. To increase the number of EHP submissions, CNISP has streamlined the 2023 EHP. Further, questions pertaining to hospital antimicrobial stewardship programs have been removed from the 2023 EHP and will be asked separately in a targeted survey.

OBJECTIVES

1. To characterize infection prevention and control, antimicrobial stewardship, and laboratory practices among CNISP participating hospitals in relation to AMR prevention.
2. To investigate how differences in infection prevention and control, antimicrobial stewardship, and laboratory practices affect HAI/ARO rates among CNISP participating hospitals.
3. To associate process variables captured in the EHP with short- and long-term outcomes from CNISP HAI/ARO surveillance.
METHODS

Site Eligibility
All CNISP hospitals are required to participate. It is mandatory for CNISP participating hospitals to submit annual EHP data.

Submission timeline
Data are retrospectively collected and include data from January 1st to December 31st of the previous surveillance year. Data are due by March 31st. For example, data from January 1st 2022 to December 31st 2022 are due by March 31st 2023 as part of the 2022 surveillance year.

Data submission
All data must be submitted to CNISP by March 31st of the following surveillance year for the previous surveillance year. Please submit data electronically on CNPHI via Web Data as shown below. The data collection form is found on CNPHI > Collaboration Centre > Web Data > Enhanced Hospital Profile Form.

On CNPHI, click the “Collaboration” tab at the top. On the left-hand side, click “Web Data”, and you will see the CNISP Enhanced Hospital Profile form on this page.

The questions in this profile apply to all hospitals participating in any surveillance project. One profile can be submitted for a network of hospitals if the same information applies to all hospitals in the network.

The profile contains three tabs:
1. **Hospital information**
2. **Infection prevention and control practices**
   E.g. Number of infection control professionals and epidemiologists, screening practices for select HAIs/AROs (VRE, MRSA, CPO, C. auris).
3. **Laboratory practices**
   E.g. Diagnostic testing methods for *C. difficile*, *C. auris* and CPO

Ideally, hospitals will submit data annually for all three tabs. However, if data on laboratory practices cannot be ascertained in a timely manner, please submit data for hospital information, and infection prevention and control in the meantime. Once data on laboratory practices has been ascertained, please re-visit the profile to complete these outstanding data. The Wed Data form can be modified after submission.

**Analysis**
Data will be reported through PHAC surveillance reports, presentations, publications, and published on the PHAC and/or AMMI website.

**ETHICS**

While this surveillance project is observational and does not involve any alteration in patient care, ethics approval may be sought at some hospital sites. Surveillance is a routine component of quality assurance and patient care in Canadian healthcare institutions and therefore informed consent is not required. All data submitted to the Agency are kept strictly confidential.

**PRIVACY**

Any data released by CNISP will be in summary format and will not identify individual hospitals. Hospital administrators should be made aware that national and/or regional reporting of aggregate data will occur.

**REFERENCES**

# Appendix 1 - Questionnaire

These questions are for all acute care hospitals who participated in any CNISP surveillance projects in the previous surveillance year. Please complete one questionnaire for each acute care hospital which was assigned a CHEC number in the previous surveillance year.

<table>
<thead>
<tr>
<th>HOSPITAL INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHEC Site Number:</strong> Please complete a separate survey for each site where responses differ.</td>
</tr>
<tr>
<td><strong>Surveillance Year:</strong> Please indicate the surveillance year (ex. 2020).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INFECTION CONTROL AND PREVENTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Please indicate each individual site’s full-time equivalent (FTE) for the staff members indicated below:</td>
</tr>
<tr>
<td>• Medical Director for Infection Prevention and Control ______</td>
</tr>
<tr>
<td>• Infection Control Professionals ______</td>
</tr>
<tr>
<td>• Epidemiologic Support ______</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. For the specified surveillance year, did this hospital conduct screening(^1) for VRE?</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ No</td>
</tr>
<tr>
<td>If no, what year did this hospital stop screening patients for VRE? ______</td>
</tr>
<tr>
<td>□ Yes</td>
</tr>
<tr>
<td>If yes, screening conducted on...</td>
</tr>
<tr>
<td>□ all patients on admission</td>
</tr>
<tr>
<td>□ high risk patients on admission, please select all that apply:</td>
</tr>
<tr>
<td>□ patients who previously tested positive</td>
</tr>
<tr>
<td>□ patients with known exposure (i.e. outbreak, close contact)</td>
</tr>
<tr>
<td>□ patients with a previous hospital admission in the last 12 months</td>
</tr>
<tr>
<td>□ ICU patients</td>
</tr>
<tr>
<td>□ transplant patients (includes solid organ, bone marrow and stem cell transplant)</td>
</tr>
<tr>
<td>□ hematology/oncology patients</td>
</tr>
<tr>
<td>□ dialysis patients (includes hemodialysis and peritoneal dialysis)</td>
</tr>
<tr>
<td>□ other not included above, please specify: ___________________</td>
</tr>
<tr>
<td>□ patients on transfer from another healthcare facility (includes long-term care)</td>
</tr>
<tr>
<td>□ patients during hospitalization (e.g. periodic screens, etc.), please select all that apply:</td>
</tr>
<tr>
<td>□ ICU patients</td>
</tr>
<tr>
<td>□ transplant patients (includes solid organ, bone marrow and stem cell transplant)</td>
</tr>
<tr>
<td>□ hematology/oncology patients</td>
</tr>
<tr>
<td>□ dialysis patients (includes hemodialysis and peritoneal dialysis)</td>
</tr>
</tbody>
</table>
patients on acute medical wards
patients on general surgical wards
patients on specialized surgical wards
other not included above, please specify: ___________________

other, please specify: ___________________

For the specified surveillance year, did this hospital screen contacts of newly identified VRE cases?

- Yes
  - If yes, screening of:
    - only close contacts (i.e. same room)
    - all ward contacts
    - other, please specify: ___________________

- No

For the specified surveillance year, in this hospital were additional precautions (i.e. gown, gloves) put in place for patients with VRE?

- Yes
  - Yes, but only patients with active infections
  - No

For the specified surveillance year, in this hospital were any of the following room allocations put in place for patients with VRE most of the time? Please select all that apply.

- N/A - VRE screening is not conducted in this hospital
- Private room
- Cohort (patients with VRE are all cared for in the same room)
- Bedside isolation if multi bed rooms
- Patients with VRE are not isolated or accommodated differently than other patients (and therefore may share a room with a patient who is not VRE positive)
- Other, please specify: ___________________

3. For the specified surveillance year, did this hospital conduct screening\(^1\) for MRSA?

- No

- Yes
  - If yes, screening conducted on...
    - all patients on admission
    - high risk patients on admission, please select all that apply:

\(^1\) Screening is defined as a process to identify patients at risk for being colonized with antibiotic resistant organisms and, if risk factors are identified, obtaining appropriate specimens. Source: Provincial Infectious Diseases Advisory Committee (PIDAC) available at URL: https://www.publichealthontario.ca/en/eRepository/PIDAC-IPC_Annex_A_Screening_Testing_Surveillance_AROs_2013.pdf
patients who previously tested positive
patients with known exposure (i.e. outbreak, close contact)
patients with a previous hospital admission in the last 12 months
ICU patients
transplant patients (includes solid organ, bone marrow and stem cell transplant)
hematology/oncology patients
dialysis patients (includes hemodialysis and peritoneal dialysis)
patients who have risk factors for community-associated MRSA (e.g. IV drug use, homelessness, reside in communities with high prevalence of MRSA)
other not included above, please specify: ___________________

patients on transfer from another healthcare facility (includes long-term care)

patients during hospitalization (e.g. periodic screens, etc.), please select all that apply:
ICU patients
transplant patients (includes solid organ, bone marrow and stem cell transplant)
hematology/oncology patients
dialysis patients (includes hemodialysis and peritoneal dialysis)
patients on acute medical wards
patients on general surgical wards
patients on specialized surgical wards
other not included above, please specify: ___________________

other, please specify: __________________

For the specified surveillance year, in this hospital were any of the following room allocations put in place for patients with MRSA most of the time? Please select all that apply.

Private room
Cohort (patients with MRSA are all cared for in the same room)
Bedside isolation if multi bed rooms
Patients with MRSA are not isolated or accommodated differently than other patients (and therefore may share a room with a patient who is not MRSA positive)
Other, specify: ________________

4. For the specified surveillance year, did this hospital conduct screening\(^2\) for CPOs (i.e. CPE and CPA)?

No
Yes
If yes, screening conducted on...

all patients on admission

high risk patients on admission, please select all that apply:

patients who previously tested positive

---

\(^2\) Screening is defined as a process to identify patients at risk for being colonized with antibiotic resistant organisms and, if risk factors are identified, obtaining appropriate specimens. Source: Provincial Infectious Diseases Advisory Committee (PIDAC) available at URL: https://www.publichealthontario.ca/en/eRepository/PIDAC-IPC_Annex_A_Screening_Testing_Surveillance_AROs_2013.pdf
☐ patients with a history of travel outside of Canada in the past 12 months (please specify from which country/region: ___________________)
☐ patients hospitalized outside of Canada in the past 12 months (please specify in which country/region: ___________________)
☐ patients with known exposure (i.e. outbreak, close contact)
☐ patients with a previous hospital admission in Canada in the past 12 months
☐ ICU patients
☐ transplant patients (solid organ, bone marrow and stem cell transplant)
☐ hematology/oncology patients
☐ dialysis patients (includes hemodialysis and peritoneal dialysis)
☐ other not included above, please specify: ___________________

☐ patients on transfer from another healthcare facility (includes long-term care)

☐ patients during hospitalization (e.g. periodic screens, etc.), please select all that apply:
  ☐ ICU patients
  ☐ transplant patients (includes solid organ, bone marrow and stem cell transplant)
  ☐ hematology/oncology patients
  ☐ dialysis patients (includes hemodialysis and peritoneal dialysis)
  ☐ patients on acute medical wards
  ☐ patients on general surgical wards
  ☐ patients on specialized surgical wards
  ☐ other not included above, please specify: ___________________

☐ other, please specify: ___________________

---

**For the specified surveillance year, in this hospital were any of the following room allocations put in place for patients with a CPO most of the time? Please select all that apply.**

☐ This hospital did not identify any CPO positive patients
☐ Private room
☐ Cohort (patients with a CPO are all cared for in same room)
☐ Bedside isolation if multi bed rooms
☐ Patients with a CPO are not isolated or accommodated differently than other patients (and therefore may share a room with a patient who is not CPO positive)
☐ Other, specify: ____________________________________________________________________________

---

**5. For the specified surveillance year, did this hospital have a policy in place to conduct screening for C. auris?**

☐ No

☐ Yes

If yes, are recommendations different for pan-susceptible C. auris and MDR C. auris?

☐ No

☐ Yes, for pan-susceptible C. auris, we do not use additional precautions or screen roommates/wardmates

☐ Yes, for pan-susceptible C. auris, we use additional precautions but we do not screen roommates/wardmates

---

3 **Screening is defined as a process to identify patients at risk for being colonized with antibiotic resistant organisms and, if risk factors are identified, obtaining appropriate specimens. Source: Provincial Infectious Diseases Advisory Committee (PIDAC) available at URL:**
Yes, other, please specify: ________________________

If yes, which patient population(s) are included in the policy?

High risk patients on admission, please select all that apply:

- Patients recently hospitalized in the Indian subcontinent (e.g. in the past 12 months)
- Patients recently hospitalized outside of Canada (e.g. in the past 12 months; please specify in which country/region: ________________)
- Patients with a history of travel to the Indian subcontinent in the past 12 months
- Patients who are CPO colonized or infected
- Patients who are CPO colonized or infected AND have a history of hospitalization in other countries (if only some countries, please specify ____________________)
- Other, please specify: ________________________

Patients during admission

- Patients with exposure to antifungals, please specify: ________________________
- Roommates of a patient identified as colonized/infected with a resistant C. auris isolate
- Ward-mates of a patient identified as colonized/infected with a resistant C. auris isolate
- Patients who have spent time in a room potentially contaminated by a patient colonized/infected with a resistant C. auris isolate
- Other, please specify: ________________________

Are additional precautions (e.g. contact precautions) used for roommates with a significant exposure (as defined by your hospital) to a patient colonized by a resistant C. auris isolate (either in practice or according to policy)?

- No, not unless they become colonized/infected themselves
- Yes, until they have been screened once and found to be negative
- Yes, until they have been screened 2 or 3 times and found to be negative
- Yes, until discharge
- Yes, other, please specify: ________________________

How long does your hospital follow roommates of a positive C. auris patient (either in practice or according to policy)?

- We do not follow roommates of a positive C. auris patient
- Until discharge
- For 3 weeks
- For 4 weeks
- Other, please specify: ________________________

How frequently are roommates of a positive C. auris patient tested during the above follow up period (either in practice or according to policy)?

- Weekly
- Twice per week

---

4 Indian subcontinent includes: India, Sri Lanka, Bangladesh, Pakistan, Bhutan, Maldives, Nepal and Afghanistan
5 Patient follow up is defined as surveillance testing after initial exposure and not how long the patient is flagged in electronic medical records or laboratory information systems
How long does your hospital follow* wardmates of a positive *C. auris* patient (either in practice or according to policy)?

- We do not follow wardmates of a positive *C. auris* patient
- Until discharge
- For 3 weeks
- For 4 weeks
- Other, please specify: _________________________________

How frequently are wardmates of a positive *C. auris* patient tested during the above follow up period (either in practice or according to policy)?

- Weekly
- Twice per week
- Biweekly (i.e. every two weeks)
- Other, please specify: _________________________________
- N/A – do not follow wardmates

### LABORATORY PRACTICES

1. **What is the current *C. difficile* testing method for this hospital?**

   - PCR only
   - EIA for GDH or toxin A and B only
   - PCR followed by EIA for GDH or toxin A and/or B
   - EIA for GDH or toxin A and B followed by PCR
   - Cell cytoxin assay
   - Other, please specify: _______________________________

2. **What are the current CPO screening methods for this hospital? Please select all that apply.**

   - MIC/disk testing for a carbapenem
   - Chromogenic agar plate - ChromID CARBA smart
   - Chromogenic agar plate - Brilliant CRE
   - In house McConkey with carbapenem
   - Other: ___________________
   - N/A (we don’t screen)

   **What are the current CPO confirmatory testing methods for this hospital? Please select all that apply.**

   - PCR
   - Immunochromatographic lateral flow assay (e.g. Carba5, RESIST-4)
   - ROSCOE neo-rapid carba
   - Phenotypic testing - mCIM
   - Phenotypic testing - CARBA-NP
   - Phenotypic testing - Beta-CARBA
   - Phenotypic testing - Other: ___________________
Which of the following carbapenemases does your hospital or provincial reference lab confirm?

- KPC
- NDM
- VIM
- IMP
- GES
- NMC-A/IMI
- SME
- OXA-24
- OXA-48
- OXA-58
- OXA-237
- OXA-143
- All of the above

3. Which types of *Candida* isolates does this hospital lab identify to the species level (or send to a reference lab to identify to the species level)? Please select all that apply.

- All clinically significant *Candida* isolates
- No *Candida* isolates
- Isolates from blood cultures
- Isolates from CSF cultures
- Isolates from cultures of other sterile sites
- Some isolates from non-sterile sites (please specify the criteria: ___________________)

For which types of *Candida* isolates does this hospital perform (or send to reference lab for) antifungal susceptibility testing? Please select all that apply.

- All clinically significant *Candida* isolates
- No *Candida* isolates
- All isolates from blood cultures (i.e. at least one isolate per episode of candidemia)
- All isolates from CSF cultures (i.e. at least one isolate per episode)
- All isolates from cultures of other sterile sites (i.e. other than blood and CSF)
- Some isolates from blood cultures (specify criteria: ____________)
- Some isolates from cultures of other sterile sites (i.e. other than blood; specify criteria: ____________)
- Some isolates from non-sterile sites (specify criteria: ____________)

If this hospital performs surveillance for *C. auris*, what specimens are collected?

- Groin
- Axilla
- Combination axilla/groin
- Rectal
- Nares
- Urine
- Other, please specify: ______________

Does this hospital have a laboratory procedure/SOP for processing screening swabs from patients to detect colonization with *C. auris* (e.g. for exposed contacts of a case)?
1. No (or not yet)
2. Yes, we use the CDC protocol
3. Yes, we would send to our provincial laboratory, which has a procedure
4. Yes, we have our own policy/procedure

| 4. | Total number of unique enterococcal blood culture isolates (bacteremias) identified from inpatients only in this hospital from January-December, for the specified surveillance year (excluding repeat isolates): ________ |
| 5. | Which respiratory viruses does your hospital test for? Please select all that apply. |
| 6. | Do you test all admissions with respiratory tract infections? |
| 7. | Which platform(s) does your hospital use to test for viral respiratory infections? |
- Extended viral panel: Biofire Film Array
- Extended viral panel: Seegene
- Extended viral panel: Luminex (Verigene/NxTag)
- Extended viral panel: Homemade
- Limited respiratory panel (Influenza/Covid/RSV): Genexpert Xpress (Cepheid)
- Limited respiratory panel (Influenza/Covid/RSV): Diasorin (Simplexa)
- Limited respiratory panel (Influenza/Covid/RSV): Roche Cobas
- Limited respiratory panel (Influenza/Covid/RSV): Luminex (Verigene)
- Limited respiratory panel (Influenza/Covid/RSV): IMDx (Abbot)
- Limited respiratory panel (Influenza/Covid/RSV): IDNow
- Limited respiratory panel (Influenza/Covid/RSV): Qiagen
- Limited respiratory panel (Influenza/Covid/RSV): Quidel
- Limited respiratory panel (Influenza/Covid/RSV): Homemade
- Other, please specify:_________________
Appendix 2 – Data dictionary

Hospital information

CHEC Site #

This will be the 3-character alphanumeric number assigned to your institution. It will always begin with the two digit number assigned to your CHEC member e.g., 07, 15, and a letter assigned by the CHEC member for that specific institution e.g., A, B, C, etc. The CHEC site # for each institution should always be the same for all the CHEC/CNISP surveillance projects and will always have all three alphanumeric digits reported as the CHEC site #, e.g., 07A, 15A.

Surveillance Year.

Please indicate the surveillance year (ex. 2020) of the report you are filling out.

Infection Prevention and Control

1. Number of medical staff (medical directors, infection control professionals, epidemiologists)

Please indicate if you have these medical staff at your hospital and how many full-time equivalent (FTE) staff of each type in your hospital.

2. VRE screening in the surveillance year.

Please check yes or no if your hospital conducted screening for VRE in the surveillance year. Screening is defined as a process to identify patients at risk for being colonized or infected with an antibiotic resistant organism (VRE) and, if risk factors are identified, obtaining appropriate specimens.

a. If no, please specify which year your hospital stopped screening for VRE screening.

b. If yes, who was screening conducted on.

Please indicate which type of patient VRE screening was conducted on: all patients on admission, high risk patients on admission, patients on transfer from another healthcare facility, patients during hospitalization, and/or other. If other is selected, please specify.

c. If high risk patients on admission, specify who.

Patients who previously tested positive, patients with known exposure (i.e. outbreak, close contact), ICU patients, transplant patients (includes solid organ, bone marrow and stem cell transplant), hematology/oncology patients, dialysis patients (includes hemodialysis and peritoneal dialysis), patients with a previous hospital admission (< 12 months) and/or other. If other is selected, please specify.

d. If patients during hospitalization, specify who.
ICU patients, transplant patients (includes solid organ, bone marrow and stem cell transplant), hematology/oncology patients, dialysis patients (includes hemodialysis and peritoneal dialysis), patients on acute medical wards, patients on general surgical wards, patients on specialized surgical wards and/or other. If other is selected, please specify.

Contacts of VRE cases

Please indicate if your hospital screened contacts of newly identified VRE cases in the specific surveillance year. If yes, please specify what type of contacts were screened.

Additional precautions for VRE

Please indicate if your hospital took additional precautions (e.g. gown or gloves) for patients colonized or infected with VRE.

Room allocations for patients colonized or infected with VRE

Please select the room allocations put in place for patients colonized or infected with VRE. If VRE screening was not conducted at your hospital in the surveillance year, select N/A.

3. MRSA screening in the surveillance year.

Please check yes or no if your hospital conducted screening for MRSA in the surveillance year.

a. If yes, who was screening conducted on.

Please indicate which type of patient MRSA screening was conducted on: all patients on admission, patients on transfer from another healthcare facility (includes long-term care), high risk patients on admission, patients during hospitalization (e.g. periodic screens, etc.) and/or other. If other is selected, please specify.

b. If high risk patients on admission, specify who.

Patients who previously tested positive, patients with known exposure (i.e. outbreak, close contact), ICU patients, transplant patients (includes solid organ, bone marrow and stem cell transplant), hematology/oncology patients, dialysis patients (includes hemodialysis and peritoneal dialysis), patients with a previous hospital admission (< 12 months), patients who have risk factors for community-associated MRSA (e.g. IV drug use, homelessness, reside in communities with high prevalence of MRSA) and/or other. If other is selected, please specify.

c. If patients during hospitalization, specify who.

ICU patients, transplant patients (includes solid organ, bone marrow and stem cell transplant), hematology/oncology patients, dialysis patients (includes hemodialysis and peritoneal dialysis), patients on acute medical wards, patients on general surgical wards, patients on specialized surgical wards and/or other. If other is selected, please specify.

Room allocations for patients colonized or infected with MRSA
Please select the room allocations put in place for patients colonized or infected with MRSA. If MRSA screening was not conducted at your hospital in the surveillance year, select N/A.

4. **CPO screening in the surveillance year.**

   Please check yes or no if your hospital conducted screening for CPO (i.e. CPE, CPA) in the surveillance year.

   a. **If yes, who was screening conducted on.**

      Please indicate which type of patient CPO screening was conducted on: all patients on admission, patients on transfer from another healthcare facility (includes long-term care), high risk patients on admission, patients during hospitalization (e.g. periodic screens, etc.) and/or other. If other is selected, please specify.

   b. **If high risk patients on admission, specify who.**

      Patients who previously tested positive, patients with a history of travel outside of Canada in the past 12 months, patients hospitalized outside of Canada in the past 12 months, patients with known exposure (i.e. outbreak, close contact), ICU patients, transplant patients (solid organ, bone marrow and stem cell transplant), hematology/oncology patients, dialysis patients (includes hemodialysis and peritoneal dialysis), patients with a previous hospital admission in Canada (< 12 months) and/or other. If other is selected, please specify.

   c. **If patients with a history of travel/hospitalization outside of Canada, please specify the country/region.**

   d. **If patients during hospitalization, specify who.**

      ICU patients, transplant patients (includes solid organ, bone marrow and stem cell transplant), hematology/oncology patients, dialysis patients (includes hemodialysis and peritoneal dialysis), patients on acute medical wards, patients on general surgical wards, patients on specialized surgical wards and/or other. If other is selected, please specify.

Room allocations for patients colonized or infected with CPO.

Please select the room allocations put in place for patients colonized or infected with CPO. If CPO screening was not conducted at your hospital in the surveillance year, select N/A.

5. **C. auris (Candida auris) screening in the surveillance year.**

   Please check yes or no if your hospital had a policy in place to conduct screening for *C. auris* in the surveillance year.

   a. **If yes, are recommendations different for pan-susceptible *C. auris* and MDR *C. auris?**

      Select yes or no.

   b. **If yes, who was screening conducted on.**

      Please indicate which type of patient *C. auris* screening was conducted on: high risk patients on admission,
patients during admission and/or other. If other is selected, please specify.

c. **If high risk patients on admission, specify who.**

Patients recently hospitalized in the Indian subcontinent (e.g. in the past 12 months), patients recently hospitalized outside of Canada (e.g. in the past 12 months), patients who are CPO colonized or infected, patients with a history of travel to the Indian subcontinent in the past 12 months, patients who are CPO colonized or infected AND have a history of hospitalization in other countries and/or other. If other is selected, please specify.

d. **If patients during admission, specify who.**

Roommates of a patient identified as colonized/infected with a resistant C. auris isolate, ward-mates of a patient identified as colonized/infected with a resistant C. auris isolate, patients who have spent time in a room potentially contaminated by a patient colonized/infected with a resistant C. auris isolate and/or with exposure to antifungals.

Additional precautions used for roommates with a significant exposure (as defined by your hospital) to a patient colonized by a resistant *C. auris* isolate (either in practice or according to policy).

Length of follow-up for roommates of a positive *C. auris* patient (either in practice or according to policy).

Frequency of testing of roommates of a positive *C. auris* patient (either in practice or according to policy).

Length of follow-up for wardmates of a positive *C. auris* patient (either in practice or according to policy).

Frequency of testing of wardmates of a positive *C. auris* patient (either in practice or according to policy).

---

**Laboratory Practices**

1. **C. difficile lab testing**

   Please select the current laboratory testing method for *C. difficile* at your hospital. If a combination of methods are used, please specify which tests are used exactly.

2. **CPO lab testing**

   Please select the current CPO screening and confirmatory testing methods at your hospital. Please specify which carbapenemase(s) your hospital or provincial reference lab identifies/confirmed.

3. **C. auris lab testing**

   Please select which type of isolate(s) your lab identifies to the species level. Please specify if your lab performs or receives results from antifungal susceptibility tests. Please specify for which isolate(s) antifungal susceptibility testing is performed (either by your hospital lab or reference lab). If your hospital performs surveillance for *C. auris*, please specify which specimens are collected. Please specify what method(s) your hospital lab or reference lab use to perform antifungal susceptibility testing. Please specify what interpretive
criteria your lab uses for antifungal susceptibility testing. Please specify if your hospital has a laboratory procedure/SOP for processing screening swabs from patients to detect colonization with C. auris (e.g. for exposed contacts of a case).

4. Screening isolates

Please indicate the number of unique enterococcal blood culture isolates from bloodstream infections identified among inpatients in this hospital from January – December of the surveillance year. Please exclude repeat isolates.

Please indicate the total number of screening tests performed by your hospital in the surveillance year for CPO, VRE and MRSA.

5. Viral respiratory illness

a. **Please specify the respiratory viruses your hospital tests for.**

   - Influenza A, Influenza B, Enterovirus, Rhinovirus, Enterovirus/Rhinovirus, RSV, Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, Metapneumovirus, Adenovirus, Bocavirus, Corona229E, CoronaHKU1, CoronaNL63, CoronaOC43, SARS-CoV-2

b. **If you test for influenza A, please specify if you are able to perform subtyping (e.g. H3N2, H1N1).**

c. **Please specify if you test all admissions with respiratory tract infections?**

d. **If you do NOT test all admissions with respiratory tract infections, please specify which patient population(s) your hospital tests.**

   Admissions with severe RTI (e.g. ICU), admissions of immunocompromised hosts, all nosocomial respiratory tract infections, selected nosocomial respiratory tract infections, restricted to ID and/or other. If other, please specify.

e. **Please specify the platform(s) your site uses to test for viral respiratory infections.**

   - Extended viral panel: Biofire Film Array
   - Extended viral panel: Seegene
   - Extended viral panel: Luminex (Verigene/NxTag)
   - Extended viral panel: Homemade
   - Limited respiratory panel (Influenza/Covid/RSV): Genexpert Xpress (Cepheid)
   - Limited respiratory panel (Influenza/Covid/RSV): Diasorin (Simplexa)
   - Limited respiratory panel (Influenza/Covid/RSV): Roche Cobas
   - Limited respiratory panel (Influenza/Covid/RSV): Luminex (Verigene)
   - Limited respiratory panel (Influenza/Covid/RSV): IMDx (Abbott)
   - Limited respiratory panel (Influenza/Covid/RSV): IDNow
   - Limited respiratory panel (Influenza/Covid/RSV): Qiagen
   - Limited respiratory panel (Influenza/Covid/RSV): Quidel
   - Limited respiratory panel (Influenza/Covid/RSV): Homemade
   - Other